Monitoring renal function in hypertension

British Medical Journal

Volumn 333, Issue 7574, 2006, Pages 896-899

  Martin, Una ^a   Coleman, Jamie J ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; LISINOPRIL; MOXONIDINE; PERINDOPRIL; POTASSIUM SPARING DIURETIC AGENT; SPIRONOLACTONE;

BLOOD PRESSURE MONITORING; BRONCHOSPASM; CLINICAL FEATURE; CREATININE BLOOD LEVEL; EPISTAXIS; HUMAN; HYPERTENSION; KIDNEY ARTERY STENOSIS; KIDNEY FUNCTION; KIDNEY FUNCTION TEST; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NOSE CONGESTION; NUCLEAR MAGNETIC RESONANCE IMAGING; POTASSIUM BLOOD LEVEL; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RENOVASCULAR DISEASE; REVIEW;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DIURETICS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY DISEASES; MIDDLE AGED; RECEPTORS, ANGIOTENSIN;

EID: 33750575670     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.38987.502512.DE     Document Type: Review

References (13)

1. Iglesias JI, Hamburger RJ, Feldman L, Kaufman JS. The natural history of incidental renal artery stenosis in patients with aortoiliac vascular disease. Am J Med 2000;109:642-7.
2. Smellie WSA. Best practice in primary care pathology: review 6. J Clin Pathol 2006; doi: 10.1136/jcp.2006.040014
3. Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med 2002;347:1256-61.
4. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000;160:685-93.
5. Main J. When should atheromatous renal artery stenosis be considered? A guide for the general physician. Clin Med 2003;3:520-5.
6. Safian RD, Textor SC. Renal-artery stenosis. N Engl J Med 2001;344:431-42.
7. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
8. McMurray J, Cohen-Solal A, Dietz R, Eichhorn E, Erhardt L, Hobbs R, et al. Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. Eur J Heart Fail 2001;3:495-502.
9. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. Guidelines for management of hypertension: Report of the fourth working party of the British Hypertension Society, 2004-BHSIV. J Hum Hypertens 2004;18:139-85.
10. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004;351:585-92.
11. McMurray JJV, O'Meara E. Treatment of heart failure with spironolactone-trial and tribulations. N Engl J Med 2004;351:526-8.
12. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004;351:543-51.
13. National Institute for Health and Clinical Excellence. Hypertension: management of hypertension in adults in primary care. Partial update of NICE clinical guideline 18. London: NICE, 2006.